Rigel Ready To Hit The Ground Running After Early AML Drug Approval
Rezlidhia PDUFA Date Was Mid-February
Rezlidhia, which was only recently licensed by Rigal from Novo Nordisk-owned Forma Therapeutics, should challenge the market dominance of Servier's Tibsovo in the IDH-1 inhibitor subset of acute myeloid leukemia patients.
You may also be interested in...
Keeping Track: Rebyota, Rezlidhia Rev Up US FDA Approvals; New Sponsors Sought For Poziotinib, Brexafemme
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.
Novo Nordisk’s Forma Buy Builds On Foothold In Rare Blood Disorders
Novo's head of rare disease Ludovic Helfgott talked to Scrip about the $1.1bn acquisition and expansion into sickle cell disease.
Rigel’s Tavalisse Hits Pothole In Label Expansion For Hemolytic Anemia
Tavalisse misses the primary endpoint in a 90-patient Phase III trial in warm autoimmune hemolytic anemia, but Rigel contends a high placebo response in Eastern Europe confounded the results.